Stroke · adults with or without existing CVD
It is very uncertain whether high changes stroke compared with low alpha‐linolenic acid omega‐3 fats (very low certainty).
1 finding from 1 review
Stroke · adults with or without existing CVD
High showed no clear difference in stroke compared with low long‐chain omega‐3 fats (moderate certainty).
1 finding from 1 review
Acute ischaemic stroke · adults undergoing cardiac surgery with cardiopulmonary bypass
It is very uncertain whether high changes acute ischaemic stroke compared with low blood pressure target (very low certainty).
1 finding from 1 review
Fatal or nonfatal stroke · adults with or without existing CVD
It is very uncertain whether higher changes stroke: fatal or non‐fatal Study duration range 24‐96 months Omega‐6… compared with lower omega‐6: primary outcomes (very low certainty).
1 finding from 1 review
Stroke · people with or without existing CVD, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in stroke compared with lower PUFA (low certainty).
1 finding from 1 review
Stroke · people with or without existing cardiovascular disease, men and women
It is very uncertain whether homocysteine‐lowering interventions (high dose) changes stroke compared with homocysteine‐lowering interventions (low dose) (very low certainty).
1 finding from 1 review
Stroke · Adults with coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stroke · overweight or obese adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in any stroke compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower any stroke compared with placebo (high certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower any stroke compared with placebo (high certainty).
1 finding from 1 review
Stroke · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in stroke (total) compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Stroke · any patient population and people with high cardiovascular risk
Colchicine showed no clear difference in stroke (total) compared with any control treatment (low certainty).
1 finding from 1 review
Intervention not reported
Stroke (non‐fatal) · people with cardiovascular disease or at high risk of cardiovascular disease
The intervention probably leads to lower stroke (non‐fatal) (moderate certainty).
1 finding from 1 review
Fatal and non‐fatal ischaemic stroke · people with coronary disease, ischaemic cerebrovascular disease, peripheral arterial disease or at high risk of atherothrombotic disease
clopidogrel plus aspirin probably leads to lower fatal and non‐fatal ischaemic stroke compared with aspirin alone (moderate certainty).
1 finding from 1 review
Clinical CVD events (CVD mortality, non‐fatal MI and stroke, revascularisations) · people at high risk of or withcardiovascular disease
Transcendental meditation (TM) showed no clear difference in clinical CVD events (CVD mortality, non‐fatal MI and stroke,… compared with active comparators (low certainty).
1 finding from 1 review